Summary

Market for melanoma detection is large and growing

Unmet medical need

MelaFind® is a breakthrough product for early detection

Strong clinical trial results (>3,500 patients studied)

FDA Protocol Agreement in place for Pivotal Trial – initiate in 2006

Strong business model for commercial launch

About EOS

We are a medical device company focused on the design and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. Our flagship product, MelaFind®, features a hand-held imaging device that emits multiple wavelengths of light to capture images of suspicious pigmented skin lesions and extract data. The data are then analyzed against our proprietary database of melanomas and benign lesions using sophisticated algorithms in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

MelaFind ® is currently under clinical investigation and is not yet available for commercial distribution in the United States or any other country. We have entered into a binding Protocol Agreement with the US Food and Drug Administration, which is an agreement for the conduct of the pivotal trial in order to establish the safety and effectiveness of MelaFind®. We believe the presence of the Protocol Agreement significantly enhances our ability to expedite the FDA
approval process.